Showing 5281-5290 of 5909 results for "".
- Palatin Technologies Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial With PL9643https://modernod.com/news/palatin-technologies-announces-first-patient-enrolled-in-dry-eye-disease-phase-2-clinical-trial-with-pl9643/2477303/Palatin Technologies announced that it has enrolled the first patient in a phase 2 clinical trial of topical PL9643, a melanocortin 1/5 receptor (MC1/5r) agonist, for the treatment of dry eye disease (DED). “We are pleased to initiate this phase 2 study of PL9643 exploring treatment
- Not All With AMD May Need Continuing Treatmenthttps://modernod.com/news/not-all-with-amd-may-need-continuing-treatment/2477294/A small number of patients with neovascular age-related macular degeneration (AMD) continue to maintain good vision years after cessation of anti-VEGF therapy, according to an analysis of trial results, as reported by Reuters. Howe
- Calvin Roberts, MD, Named President and CEO of Lighthouse Guildhttps://modernod.com/news/calvin-roberts-md-named-president-and-ceo-of-lighthouse-guild/2477286/Calvin Roberts, MD, has been elected President and CEO of Lighthouse Guild. Dr. Roberts will leave his position as Senior Vice President and Chief Medical Officer, Eye Care, at Bausch Health Companies, on March 31. Dr. Roberts i
- Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)https://modernod.com/news/oculis-announces-positive-ocs-01-phase-2-data-in-patients-with-diabetic-macular-edema-dme/2477287/Oculis reported positive data from a phase 2 study of OCS-01, a novel eye drop formulation of dexamethasone, in development for the treatment of diabetic macular edema (DME), according to a company news release. OCS-01 was developed using Oculis’ proprietary Soluble NanoParticle technolog
- Kodiak Sciences Announces Additional Data from Ongoing Phase 1b Study of KSI-301 in Patients With Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-announces-additional-data-from-ongoing-phase-1b-study-of-ksi-301-in-patients-with-retinal-diseases/2477282/Kodiak Sciences announced promising safety, efficacy, and durability data from the ongoing phase 1b study of its investigational therapy KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular degener
- ProQR Therapeutics Teams Up With Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker Program for People With Inherited Retinal Diseaseshttps://modernod.com/news/proqr-therapeutics-teams-up-with-foundation-fighting-blindness-and-blueprint-genetics-to-support-the-my-retina-tracker-program-for-people-with-inherited-retinal-diseases/2477280/ProQR Therapeutics, a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, announced its participation in the Foundation Fighting Blindness My Retina Tracker Program, a collaborative, open-access program run by Blueprint Geneti
- Staar Surgical Announces Strategic Cooperation Agreement with Senshinkai Eye Institute in Japanhttps://modernod.com/news/staar-surgical-announces-strategic-cooperation-agreement-with-senshinkai-eye-institute-in-japan/2477276/Staar Surgical announced that it entered a strategic cooperation agreement with Senshinkai Eye Institute (SEI), an eye care group with five locations in Japan. The agreement includes volume commitments for the company’s implantable collamer lenses (ICLs), ICL surgeon training and certification, t
- Verana Health Acquires PYA Analytics; Announces $100 Million Financinghttps://modernod.com/news/verana-health-acquires-pya-analytics-announces-100-million-financing/2477275/Verana Health announced that it has acquired the assets of data science company PYA Analytics (PYAA). Based in Knoxville, Tennessee, PYAA specializes in large-scale data architecture solutions. Terms of the deal were not disclosed. PYAA was founded in 2013 by scientists and engineer
- Acucela Meets with NASA and TRISH for Phase 1 Update for SS-OCT Projecthttps://modernod.com/news/acucela-meets-with-nasa-and-trish-for-phase-1-update-for-ss-oct-project/2477272/Acucela announced that the company was invited to meet with NASA and the Translational Research Institute for Space Health (TRISH)1 to present the status of its Swept Source-OCT (SS-OCT) device being developed for NASA’s Deep Space missions. The purpose of the meeting, which too
- ForwardVue Pharma CEO: “Short Path to the Clinic” for Retinal Disease Treatmenthttps://modernod.com/news/forwardvue-pharma-ceo-short-path-to-the-clinic-for-retinal-disease-treatment/2477263/In an interview with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco, ForwardVue Pharmaceuticals CEO Alan Franklin, MD, PhD, who is an ophthalmologist, said the company’s lead molecule aims to treat retinal neovascular disease.